Major trial aims to improve First-Line myeloma treatment, possibly eliminating need for stem cell transplant
NCT ID NCT07428369
Summary
This large study is testing a new drug combination (linvoseltamab, bortezomib, lenalidomide) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. It will compare this new combination, with and without the transplant, against the current standard treatment. A key goal is to see if the new drugs work so well that the intensive transplant procedure might not be needed for initial treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.